Shots:

• Evotec to receive research funding and will be eligible for $160M/program as discovery- pre/ clinical- a commercial milestone along with royalties on sales of product emerges from the collaboration
• The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with small-molecule ligands aligned that can be developed into the first-in-class therapeutics
• The companies will jointly identify & develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas

 ­ Ref: Evotec | Image: Wikipedia